High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: A cross-sectional study

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Shlomai, Gadi ^a,b,c   Haran Appel, Tal ^c   Sella, Tal ^a   Grossman, Yoni ^a   Hauschner, Hagit ^a   Rosenberg, Nurit ^a,c   Grossman, Ehud ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b The Dr Pinchas Borenstein Talpiot Medical Leadership Program   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aspirin; Cardiovascular risk; Diabetes mellitus; Platelets activity; Primary prevention

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 2; GLUCOSE; PADGEM PROTEIN; (4-BENZYLPIPERAZIN-1-YL)ACETIC ACID (3-ALLYL-2-HYDROXYBENZYLIDENE)HYDRAZINE; HYDRAZONE DERIVATIVE; PIPERAZINE DERIVATIVE; SELP PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKOCYTE AGGREGATION; LEUKOCYTE PLATELET AGGREGATE; MAJOR CLINICAL STUDY; MALE; MONOCYTE PLATELET AGGREGATE; NEUTROPHIL PLATELET AGGREGATE; NON INSULIN DEPENDENT DIABETES MELLITUS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; AGED; BLOOD; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; LEUKOCYTE; METABOLISM; MIDDLE AGED; MONOCYTE; NEUTROPHIL; PHYSIOLOGY; THROMBOCYTE;

AGED; BLOOD PLATELETS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDRAZONES; LEUKOCYTES; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; MONOCYTES; NEUTROPHILS; P-SELECTIN; PIPERAZINES; PLATELET AGGREGATION; PLATELET FUNCTION TESTS;

EID: 84931270915     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0244-x     Document Type: Article

References (50)

1. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003;108(13):1655-61. doi: 10.1161/01.cir.0000089189.70578.e2 .
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-94. doi: 10.1056/NEJMra071014 .
3. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46(6):937-54. doi: 10.1016/j.jacc.2005.03.074 .
4. Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719. doi: 10.1155/2011/742719 .
5. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44(2):188-95. doi: 10.1007/s001250051598 .
6. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2(8):1282-91. doi: 10.1111/j.1538-7836.2004.00836.x .
7. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol. 2003;92(11):1362-5.
8. Rollini F, Franchi F, Muniz-Lozano A, Angiolillo DJ. Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res. 2013;6(3):329-45. doi: 10.1007/s12265-013-9449-0 .
9. Watala C, Golanski J, Boncler MA, Pietrucha T, Gwozdzinski K. Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets. 1998;9(5):315-27. doi: 10.1080/09537109876564 .
10. Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost. 1992;68(5):577-82.
11. Ferretti G, Rabini RA, Bacchetti T, Vignini A, Salvolini E, Ravaglia F, et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab. 2002;87(5):2180-4. doi: 10.1210/jcem.87.5.8466 .
12. Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J. 1995;42(4):461-5.
13. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84(5):489-97.
14. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun. 1988;157(3):1190-6.
15. Trovati M, Anfossi G, Massucco P, Mattiello L, Costamagna C, Piretto V, et al. Insulin stimulates nitric oxide synthesis in human platelets, and through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate. Diabetes. 1997;46(5):742-9.
16. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17(8):577-85. doi: 10.1080/09537100600760814 .
17. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):s11-6. doi: 10.1161/atvbaha.107.159178 .
18. Seghieri G, Di Simplicio P, Anichini R, Alviggi L, De Bellis A, Bennardini F, et al. Platelet antioxidant enzymes in insulin-dependent diabetes mellitus. Clin Chim Acta. 2001;309(1):19-23.
19. Patrono C, Davi G. Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes Metab Rev. 1993;9(3):177-88.
20. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011;58(24):e44-122. doi: 10.1016/j.jacc.2011.08.007 .
21. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA. 1992;268(10):1292-300.
22. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ (Clinical research ed). 2008;337:a1840. doi: 10.1136/bmj.a1840 .
23. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-41. doi: 10.1001/jama.2008.623 .
24. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510-20. doi: 10.1001/jama.2014.15690 .
25. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010;33(6):1395-402. doi: 10.2337/dc10-0555 .
26. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. doi: 10.1016/s0140-6736(09)60503-1 .
27. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (Clinical research ed). 2009;339:b4531. doi: 10.1136/bmj.b4531 .
28. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010;87(2):211-8. doi: 10.1016/j.diabres.2009.09.029 .
29. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care. 2009;32(12):2300-6. doi: 10.2337/dc09-1297 .
30. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014 .
31. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res. 2014;11(3):133-73. doi: 10.1177/1479164114525548 .
32. D'Agostino Sr RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. doi: 10.1161/circulationaha.107.699579 .
33. Nagasawa A, Matsuno K, Tamura S, Hayasaka K, Shimizu C, Moriyama T. The basis examination of leukocyte-platelet aggregates with CD45 gating as a novel platelet activation marker. Int J Lab Hematol. 2013;35(5):534-41. doi: 10.1111/ijlh.12051 .
34. Harding SA, Din JN, Sarma J, Jessop A, Weatherall M, Fox KA, et al. Flow cytometric analysis of circulating platelet-monocyte aggregates in whole blood: methodological considerations. Thromb Haemost. 2007;98(2):451-6.
35. Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. Correlation between mean platelet volume and fasting plasma glucose levels in prediabetic and normoglycemic individuals. Cardiovasc Diabetol. 2013;12:14. doi: 10.1186/1475-2840-12-14 .
36. Stratmann B, Xu T, Meisinger C, Menart B, Roden M, Herder C, et al. PLA1A2 platelet polymorphism predicts mortality in prediabetic subjects of the population based KORA S4-Cohort. Cardiovasc Diabetol. 2014;13:90. doi: 10.1186/1475-2840-13-90 .
37. Singer J, Weissler Snir A, Leshem-Lev D, Rigler M, Kornowski R, Lev EI. Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thromb Res. 2014;134(1):121-4. doi: 10.1016/j.thromres.2014.05.010 .
38. Kimura Y, Takano K, Satoh K, Aida K, Kobayashi T, Ozaki Y. Aspirin half maximal inhibitory concentration value on platelet cyclooxygenase1 in severe type-2 diabetes mellitus is not significantly different from that of healthy individuals. Clin Appl Thromb Hemost. 2014;20(6):629-36. doi: 10.1177/1076029613488934 .
39. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation. 2001;104(2):181-6.
40. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991;17(4):433-8. doi: 10.1055/s-2007-1002650 .
41. Yngen M, Norhammar A, Hjemdahl P, Wallen NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res. 2006;3(1):52-6. doi: 10.3132/dvdr.2006.008 .
42. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med. 1998;158(18):2007-14.
43. Lemkes BA, Bahler L, Kamphuisen PW, Stroobants AK, Van Den Dool EJ, Hoekstra JB, et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. J Thromb Haemost. 2012;10(4):639-46. doi: 10.1111/j.1538-7836.2012.04632.x .
44. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313-6.
45. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-35. doi: 10.1056/nejm198907203210301 .
46. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351(9098):233-41.
47. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62.
48. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264-72.
49. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357(9250):89-95.
50. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ (Clinical research ed). 1997;315(7119):1333-7.